KBKarolina Błaszczak

Karolina Błaszczak

*This is an algorithmically generated author record based on publicly available information.

Karolina Błaszczak has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in the Treatment and Prevention of Heart Failure Based on the 2023 Focused Update of the 2021 European Society of Cardiology Guidelines

    by Joanna Skotnicka, Karolina Błaszczak, Maria Witkowska, Monika Turek, Maciej Witkowski, Tymoteusz Ślósarz, Paulina Krupa, Rafal Kaczorowski, Tomasz Forenc, Klara Wojciechowska

    Introduction and Objective:The 2023 update to the 2021 ESC Guidelines for diagnosing and treating acute and chronic heart failure introduces significant changes in pharmacotherapy and prevention. Staying informed about these updates is crucial given the evolving landscape of heart failure management. This review provides an overview of the latest recommendations and supporting evidence. Review Methods:A comprehensive review of scientific publications and guidelines from PubMed, Google Scholar, Clinical Key, Via Medica Journals, and relevant clinical guidelines was conducted to ensure the most recent evidence is considered. Brief Description of the State of Knowledge:Heart failure is a growing global concern. The 2023 update highlights key management changes. Recent trials, including EMPEROR-Preserved and DELIVER, show empagliflozin and dapagliflozin reduce heart failure hospitalization and cardiovascular death in patients with mildly reduced and preserved ejection fraction. The guidelines now recommend intravenous iron for patients with reduced or mildly reduced ejection fraction and iron deficiency. For those with type 2 diabetes and chronic kidney disease, SGLT2 inhibitors and finerenone, a non-steroidal mineralocorticoid antagonist, are recommended to reduce heart failure hospitalization and prevent renal function decline. Summary:The 2023 ESC Guidelines update offers revised recommendations for heart failure management and prevention, integrating the latest clinical trial data and meta-analyses. Key areas include the use of SGLT2 inhibitors, iron deficiency management, and preventive strategies for high-risk populations. Implementing these guidelines can significantly improve preventive and therapeutic outcomes for heart failure patients.


  • Open Access

    Optimizing Physical Activity for Glycemic Control in Type 1 Diabetes: Strategies and Risks

    by Paulina Przybysz, Maja Kucharska, Adrian Kruszewski, Monika Szyszka, Kacper Kwiliński, Natalia Paduszyńska, Anna Dąbrowska, Karolina Błaszczak, Barbara Wawrzyńska

    Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas, necessitating lifelong insulin therapy. This study explores the impact of physical activity on glycemic control and overall health in individuals with T1DM. Despite its proven benefits, including improved cardiovascular health, lower HbA1c levels, and reduced insulin requirements, over 60% of T1DM patients do not engage in regular exercise. Different types of physical activities—such as aerobic, anaerobic, and high-intensity interval training (HIIT)—affect metabolic responses differently. Aerobic exercises and HIIT have shown significant improvements in health-related quality of life (HRQoL) and reduced incidence of severe complications, such as diabetic ketoacidosis. However, exercise-induced hypoglycemia remains a significant risk, especially if exercise follows recent severe hypoglycemic episodes. Proper management strategies include adjusting insulin doses, monitoring glucose levels, and carbohydrate intake. The study highlights the importance of tailored exercise plans and preventive measures to mitigate risks such as nocturnal hypoglycemia and elevated ketones. Ultimately, effective integration of physical activity into diabetes management can lead to enhanced overall health and quality of life for individuals with T1DM.


  • Open Access

    Rett syndrome – advances in gene and trofinetide therapy

    by Anna Dąbrowska, Adrian Kruszewski, Natalia Paduszyńska, Karolina Błaszczak, Paulina Przybysz, Monika Szyszka, Maja Kucharska, Barbara Wawrzyńska

    Rett syndrome is a rare, severe neurodevelopmental disorder with X-linked dominant inheritance. It mainly affects women, causing cognitive and physical impairments due to rapid developmental regression in infancy. Rett syndrome is usually recognised in children between six and 18 months old, when they begin to miss developmental milestones or lose the abilities they have gained. One characteristic symptom involves continuous repetitive hand movements. Rett syndrome is one of the most common causes of complex disability in girls. However, the condition can be misdiagnosed. Differential diagnoses that should be considered include cerebral palsy, autism, Angelman syndrome, and non-specific developmental delay. Rett syndrome is related to the loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (approximately 90% of reported cases). These mutations have been associated with impacting the development of neurons and axodendritic connections. Progress has been made over the past 50 years since the first report of Rett syndrome. Several promising clinical trials and exciting novel therapeutic options are being tested in both laboratory and clinical settings. Research findings led to the registration in March 2023 of the first drug for therapy, trofinetide. The medication was found to improve brain function and communication skills in recent studies. There are also promising clinical trials investigating the replacement of the mutated gene. This study aims to analyse the latest pharmacological treatment and gene therapy in Rett syndrome, which brings a glimmer of hope to patients and their families, who anticipate a future where Rett syndrome is a reversible and curable condition.

  • Open Access

    PCOS – The Importance of Diet, Physical Activity, and Other Non-Pharmacological Methods in Treatment

    by Monika Turek, Klara Wojciechowska, Aleksandra Jaroń, Katarzyna Jastrzębska, Agata Wiklińska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Adrian Borkowski, Mateusz Sawicki

    Purpose of research: PCOS is one of the most common endocrine disorders. It is estimated to affect about 5-10% of women of reproductive age. This paper aims to highlight the challenges faced by those with PCOS and to demonstrate the importance of non-pharmacological methods in treating this condition. Methods: Databases such as PubMed, Medline, and ResearchGate were used. Basic results: PCOS is associated with menstrual irregularities and leads to reduced fertility, while commonly occurring hyperandrogenism causes unpleasant changes in appearance, such as hair loss, hirsutism, and acne. Women with PCOS also have an increased risk of developing type 2 diabetes, hypertension, and certain cancers. Conclusions: The first line of treatment for PCOS is lifestyle modification. Appropriate diet and weight loss aim to reduce inflammation, regulate the menstrual cycle, restore ovulation, and reduce the risk of cardiovascular disease and cancer. An important aspect is the intake of vitamins D and E, as well as inositol. Research shows that probiotics may also have a positive effect.

  • Open Access

    Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS

    by Aleksandra Jaroń, Agata Wiklińska, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki

    Introduction and aim of study: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting young women. It is diagnosed in individuals who meet 2 of the following 3 criteria: hyperandrogenism, ovarian dysfunction or polycystic ovarian morphology on ultrasound. A common component of this disease is obesity that leads to many serious health complications. This review paper aims to discuss the use of glucagon-like peptide-1 (GLP-1) receptor agonists as a therapeutic option to treat obesity in female patients with PCOS. Materials and Methods: The authors conducted a comprehensive review of the literature available in databases: PubMed and Medline focusing on the terms “PCOS”, “GLP-1”, “obesity”. Results: The first-line treatment of metabolic disorders in the course of PCOS is lifestyle modification. In patients who do not achieve sufficient results pharmacotherapy is recommended. Therapy with GLP-1 receptor agonists shows beneficial effects not only on weight loss, but also on metabolic and endocrine disorders. Studies have proven the superiority of these medications over metformin in the treatment of obesity associated with PCOS. However, the simultaneous use of GLP-1 receptor agonists and metformin may be beneficial for the patients. Conclusions: GLP-1 receptor agonists appear to be a promising therapeutic option in obese women with PCOS according to safety profile and effectiveness proven in studies.


  • Open Access

    Energy drinks: is there anything to be concerned about? A review of the literature with attention to the value of drinks among athletes

    by Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Aleksandra Jaroń, Katarzyna Jastrzębska, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki

    Introduction: Popular energy drinks containing caffeine, taurine or guarana are currently generating a lot of interest. Their supply is an increasingly popular method of boosting the body. Therefore, it is important to know the effects of such drinks on health. Objective: A review of the literature on the health effects of energy drinks with a focus on the value of their consumption in athletes. Current Knowledge: Many studies have been made and numerous medical cases have been analyzed to assess the health effects of energy drinks. The most commonly described complications are those involving the cardiovascular and neurological systems, but there are also cases of gastrointestinal, kidney, gynecological or skin diseases. The severity of these complications depends on the amount of energy drinks consumed and the time interval in which they were drunk. Nowadays, athletes are increasingly turning to energy drinks to boost their performance. It is also noticeable that children and adolescents who should not consume caffeine or sugar in excess consume this type of drink. Conclusions: The growing popularity of energy drinks, including among professional athletes as well as children and adolescents, is leading to an increasing number of complications due to their excessive consumption. Therefore, further research on their health effects and harmfulness is needed to determine their safe use.


  • Open Access

    Use of rimegepant as an alternative to triptans in migraine treatment

    by Aleksandra Jaroń, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki

    Introduction and aim of study: Migraine is a chronic neurological disorder that is considered one of the leading causes of disability worldwide. Increasing evidence indicates that the calcitonin gene-related peptide (CGRP), a neuropeptide released during trigeminal nerve activation, plays a major role in pathophysiology and serves as an important therapeutic target. Rimegepant is an antagonist for the receptor of this peptide and an alternative to the commonly used triptans. Materials and Methods: Two databases, Pubmed and Medline, were searched using the terms "rimegepant" and "migraine." Results: By reducing the severity and frequency of migraine attacks, rimegepant significantly improves patients' daily functioning and quality of life. A single 75 mg dose of rimegepant provided better efficacy than placebo in the acute treatment of migraine. Two hours after dosing, significantly more patients in the rimegepant group than in the placebo group reported pain relief (59.3% vs. 43.3%). Rimegepant was also effective in the long term when taken every other day for preventive treatment of migraine and/or as needed for acute migraine treatment. When used, rimegepant was well tolerated in both acute and preventive migraine treatment. The most common adverse events included nasopharyngitis, nausea, urinary tract infection, and upper respiratory tract infection. Conclusions: Rimegepant is an effective drug for treating migraine attacks, offering quick and long-lasting pain relief with a favorable safety profile, especially for patients with contraindications to triptans. Therefore, rimegepant represents a valuable alternative for patients who do not respond adequately to other available migraine therapies.

  • Open Access

    ADHD - Treatment Options and Consequences of Neglect

    by Klara Wojciechowska, Monika Turek, Aleksandra Jaroń, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Adrian Borkowski, Mateusz Sawicki

    Purpose of Research: Attention Deficit Hyperactivity Disorder (ADHD) is one of the most frequently diagnosed neurodevelopmental disorders. It is estimated to occur in approximately 5-10% of children and adolescents. This paper aims to highlight the challenges faced by individuals suffering from ADHD, present risk factors, summarize current treatment methods, and outline the consequences of neglecting treatment. Methods: Databases such as PubMed, Medline, and ResearchGate were used. Basic Results: The goal of ADHD treatment is to reduce the severity of symptoms and improve the social, academic, and emotional functioning of children and adolescents. The choice of treatment and the selection of a specific medication depend on the patient's age and coexisting disorders. Conclusions: ADHD often coexists with other mental disorders, complicating diagnosis and treatment. Lack of or ineffective treatment has consequences such as learning difficulties, disruptions in peer and family relationships. It correlates with higher rates of traffic accidents, accidental injuries, earlier onset, and higher rates of substance abuse.


  • Open Access

    role of lactoferrin in the treatment of upper respiratory tract infections

    by Marlena Cąkała, Magdalena Kozioł, Karolina Błaszczak, Kamila Podgórniak, Julia Piotrowska, Joanna Skotnicka, Aleksandra Zajkowska, Maria Witkowska

    Introduction Lactoferrin is a glycoprotein belonging to the group of transferrins found in most body fluids. It has been shown to possess antimicrobial, anti-inflammatory, immunomodulatory and anticancer properties. The increasing availability and widespread use of dietary supplements containing lactoferrin have been observed as supportive measures in managing various infections. Aim of the study The objective of this study is to summarize the current knowledge regarding the anti-infective - mostly antiviral - effects of lactoferrin and the justification for its use in the treatment of upper respiratory tract infections. Knowledge summary Scientific research has consistently confirmed the effectiveness of lactoferrin against pathogenic microorganisms. The antibacterial effect of this protein is based mainly on the management of available iron resources - an ingredient necessary for bacterial growth. On the other hand, the antiviral activity of this protein is based on the induction of interferon production. Conclusion Dietary supplements containing lactoferrin are approved by the US Food and Drug Administration (FDA) for supportive use in infections. Lactoferrin exhibits antimicrobial activity supported by research in specific infections. It has a good tolerance and safety profile, therefore it seems that it can be used adjunctively in this indication.

  • Open Access

    Review of available treatment methods for polycystic ovary syndrome (PCOS) with special emphasis on diet and physical activity

    by Marlena Cąkała, Aleksandra Zajkowska, Magdalena Kozioł, Kamila Podgórniak, Joanna Skotnicka, Karolina Błaszczak, Maria Witkowska

    Polycystic ovary syndrome (PCOS) occurs in 5 to 10% of women of reproductive age and is the most common cause of anovulation in infertile women. PCOS is associated with insulin resistance, type 2 diabetes mellitus, and increased cardiovascular risk. Although insulin resistance is not included as a criterion for diagnosis, it is a critical pathological condition of PCOS. While PCOS can pose challenges to women's health, with appropriate medical care and lifestyle modifications, symptoms can be effectively managed and the risk of associated health complications reduced. Behavioral, medical and surgical treatments have been evaluated in order to improve the fertility of women with PCOS. Lifestyle modifications (stop smoking, physical exercise and weight loss when necessary) are of the utmost importance. The aim of this paper is to present the available methods of treatment, prevention of consequences and fertility problems affecting women with PCOS.